Clinical effectiveness of the composition of muramylpeptides from gram-negative bacteria in the treatment of severe chronic generalized periodontitis
Grudyanov A.I.1, Fomenko E.V.1, Kalyuzhin, O.V.2
1 National Medical Research center of dentistry and maxillofacial surgery of the Ministry of Health of the Russian Federation, Russia, 119021, Moscow, Timura Frunze St., 16
2 Department of Clinical Immunology and Allergy, I.M. Sechenov First Moscow State Medical University, Russia, 119048, Moscow, Trubetskaya St., 8, bld. 2
The effectiveness of the immunomodulator Polymuramil (PM) was determined in the treatment of 40 patients with severe chronic generalized periodontitis based on the dynamics of the values of periodontal indices and the content of periodontal pathogens in the periodontal pockets. Patients of the main group (20 people) were treated with professional hygiene (PGO) in combination with daily intramuscular PM for 5 days at a dose of 200 mcg. Patients of the control group (20 people) were performed only PGO. The effectiveness of treatment was evaluated based on the dynamics of the clinical indices of Muehlemann and PMA and the presence or absence of major periodontal pathogens in the periodontal pockets. Results: in patients of the main group, the phenomena of periodontal inflammation and the main periodontal pathogens were eliminated in a shorter time and to a greater extent in comparison with patients of the control group.Keywords: periodontitis, periodontal indices, Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis, immunotherapy, muramyl peptides, Polymuramil.
Keywords: periodontitis, periodontal indices, Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis, immunotherapy, muramyl peptides, Polymuramil.
For citation: Grudyanov A.I., Fomenko E.V., Kalyuzhin, O.V. Clinical effectiveness of the composition of muramylpeptides from gram-negative bacteria in the treatment of severe chronic generalized periodontitis. Stomatology for All / Int. Dental Review. 2020, no.2(91), 24-29 (In Russian). doi: 10.35556/idr-2020-2(91)24-29
1. Grudyanov A.I. Periodontal disease. Moscow, 2009, 328 p. (In Russian).
2. Grudyanov A.I., Fomenko E.V. Etiology and patho-genesis of inflammatory periodontal diseases. Moscow, 2010, 90 p. (In Russian).
3. Tang L., Zhou X.D., Wang Q., Zhang L., Wang Y., Li X.Y., Huang D.M. Expression of TRAF6 and pro-inflammatory cytokines through activation of TLR2, TLR4, NOD1, and NOD2 in human periodontal ligament fibroblasts. Arch Oral Biol. 2011, 56(10): 1064—1072. doi: 10.1016 / j.archoralbio
4. Zorina O.A. Berkutova I.S. Rekhviashvili B.A. Ai-madinova N.K. Comparative characteristics of periodon-tal pockets microbiocenoses in chronic generalized and aggressive periodontitis before and after complex treat-ment. Russian Dental Journal. 2013, no.1: 27—31 (In Russian).
5. Beatriz de Brito Bezerra, Oelisoa Andriankaja, Jun Kang, Sandra Pacios, Hyung Jin Bae, Yu Li, Vincent Tsiagbe, Helen Schreiner, Daniel H. Fine, and Dana T. Graves A.actinomycetemcomitans-induced periodontal disease promotes systemic and local responses in rat periodontium. J Clin Periodontol. 2012, Apr, 39(4): 333—341.
6. Jan Oscarsson, Rolf Claesson, Mark Lindholm, Carola Hoglund Aberg, Anders Johansson. Tools of Aggregatibacter actinomycetemcomitans to Evade the Host Response. J Clin Med. 2019, Jul, 8(7): 1079. doi: 10.3390 / jcm8071079
7. Zhu, B., Macleod, L.C., Newsome, E. et al. Aggre-gatibacter actinomycetemcomitans mediates protection of Porphyromonas gingivalis from Streptococcus sanguinis hydrogen peroxide production in multi-species biofilms. Sci Rep 9, 4944 (2019). doi: 10.1038 / s41598-019-41467-9
8. Chang E.H., Giaquinto P., Huang J., Balashova N.V., Brown A.C. Epigallocatechin gallate inhibits leuko-toxin release by Aggregatibacter actinomycetemcomitans by promoting association with the bacterial membrane. Mol Oral Microbiol. 2019, Dec, 9. doi: 10.1111 / omi.12275
9. Karaulov A.V., Kalyuzhin O.V. The scope of mu-ramyl peptides in the framework of the main approaches to immunotherapy / immunoprophylaxis of infectious dis-eases. Physiology and pathology of the immune sys-tem. Immunopharmacogenomics. 2013, Vol.17, no.5: 3—15 (In Russian).
10. Dolinska E., Skurska A., Pietruska M., Dymicka V., Milewski R. Pietruski J., Sculean A. The Effect of Nonsurgical Periodical Therapy on HNP1-3 Level in Gin-gival Crevicular Fluid of Chronic Periodontitis Patients. Arch. Immunol. Ther. Exp. 2017, 65, 355—361. doi: 10.1007 / s00005-016-0451-5
11. Kalyuzhin O.V. The phenomenon of trained im-munity and mechanisms of action of non-specific immu-nomodulators. Russian Allergy Journal. 2015, no.4: 45—51 (In Russian).
12. Dagil Y.A., Arbatsky N.P., Pashenkov M.V., Alk-hazova B.I., L’vov V.L., Mazurov D.V. The dual NOD1 / NOD2 agonism of muropeptides containing a meso-diaminopimelic acid residue. PLOS ONE. 2016, 11(8). doi: 10.1371 / journal.pone.0160784
13. Kar U.K., Joosten L.A.B. Training the trainable cells of the immune system and beyond. Nat Immunol. 2020, 21: 115—119. doi: 10.1038 / s41590-019-0583-y
14. American Academy of Periodontology. Consensus report. Periodontal diseases: epidemiology and diagnosis. Annals of Periodontology. 1996, 1: 216—222. doi:10.1902/annals.19188.8.131.52
15. Bartold P.M., Van Dyke T.E. An appraisal of the role of specific bacteria in the initial pathogenesis of periodontitis. J Clin Periodontol. 2019, 46(1): 6—11. doi: 10.1111 / jcpe.13046